What Limits Membrane Loading During Sterile Filtration of a Quanshen Injectable?

Sanwei Quanshen Veterinary Grade API is processed into sterile aqueous injectables intended for swine respiratory and enteric bacterial complex therapy. The API is dispersed in Water for Injection at 40–50 °C under high-shear agitation at 3,000–5,000 rpm for a minimum of 20 minutes. Hydration of polyphenolic agglomerates is incomplete below pH 3.5; above pH 8.0 the tannin fraction undergoes accelerated oxidative browning with measurable chromophore increases at A420. The bulk solution is buffered to pH 5.5–6.5 with 0.1 M citrate buffer before filtration. The critical process limitation is membrane loading: high-molecular-weight polyphenolic aggregates in the 400–600 kDa range, quantified by size-exclusion chromatography on a TSKgel G3000SW column, reduce single-layer 0.22 µm PVDF cartridge throughput to approximately 150–250 L/m². Comparative non-phenolic small-molecule injectables typically achieve 1,500–2,000 L/m² on identical membrane area. A mandatory pre-filtration train on production-scale skids consists of a 10-inch polypropylene depth filter with 5 µm nominal retention, followed by a 0.65 µm glass-fibre prefilter, and then the final 0.22 µm PVDF membrane. Terminal sterilization at 121 °C for 15 minutes is avoided for polyphenol-rich formulations of this type: published stability data for analogous botanical APIs indicate measurable gallic acid derivative degradation and ΔA420 values exceeding 0.05 under saturated steam exposure. Aseptic filtration in a Grade A environment with Grade B background per EU GMP Annex 1 is the validated route. Bacterial retention testing is performed post-filtration on every batch. Endotoxin control follows dry-heat depyrogenation of container components at 180 °C for 60 minutes; the API supplier must provide a certified endotoxin limit, typically not exceeding 0.5 EU/mg. The finished injectable is tested per USP <787> for subvisible particles: not more than 6,000 particles ≥ 10 µm and 600 particles ≥ 25 µm per container. Bacterial endotoxin limits per USP <85> are calculated from the maximum recommended daily dose in the target species. VICH GL18 principles apply to any formulation or site change: comparative dissolution profiles or target-species pharmacokinetic studies are required. The injectable formulation typically incorporates sodium metabisulfite at 0.1% w/v as an antioxidant when the headspace oxygen level exceeds 2.0%.Injectable solutions for large-volume parenteral use in cattle require additional osmolality adjustment. The API contributes dissolved solids that raise osmolality by approximately 25–35 mOsm/kg per 10 mg/mL of extract solids. Formulations intended for intravenous administration are adjusted to 280–310 mOsm/kg with dextrose or sodium chloride. Subcutaneous and intramuscular products tolerate a wider range of 280–340 mOsm/kg without tissue irritation. Published data for histopathological irritation scoring of this specific extract in parenteral vehicles is limited. Needle gauge selection on farm is a practical constraint: formulations with viscosity exceeding 8 cP at 20 °C require 16-gauge needles for swine IM administration, which increases injection-site leakage and operator burden. Viscosity is controlled by limiting extract solids to 200 mg/mL and maintaining solution temperature above 18 °C at the point of administration. The extract exhibits moderate foaming tendency during reconstitution; vacuum deaeration at 50–100 mbar for 10 minutes is applied after high-shear mixing to eliminate entrapped air that could interfere with fill-weight accuracy on peristaltic filling lines.

Oral solution concentrates for poultry drinking water application present a different solubility profile. The API dissolves more readily in 20–30% aqueous ethanol systems, but ethanolic vehicles are prohibited in commercial layer operations where residual solvent transfer to eggs is regulated under Commission Regulation (EU) 37/2010. Water-based concentrates are therefore prepared at 100–150 mg/mL using a co-solvent system of propylene glycol (10–15% v/v) and polysorbate 80 (1–2% v/v). The finished concentrate is diluted on farm through proportioner pumps at ratios of 1:128 to 1:256, yielding final drinking-water concentrations of 0.4–1.2 mg/mL. Hard water with total hardness above 300 mg/L CaCO₃ causes gradual precipitation of calcium-tannate complexes within 6–12 hours of dilution. Addition of disodium EDTA at 0.05–0.1% w/v in the concentrate chelates divalent cations and extends physical stability of the diluted solution to 24 hours. Biofilm formation in drinking lines introduces a further degradation vector: residual polyphenols adsorb onto polyethylene pipe surfaces and provide substrate for microbial growth. Between treatment cycles, line flushing with 3% hydrogen peroxide or 0.1% peracetic acid is advised to remove adsorbed extract film. Diluted solution stability is most accurately monitored by HPLC quantification of gallic acid as a marker compound; a drop below 90% of initial marker concentration indicates oxidative or microbial degradation. The pH of diluted drinking water should be maintained between 5.0 and 7.0. Below pH 5.0, palatability declines and water consumption in broilers drops measurably, reducing total active dose delivered. Above pH 7.0, polyphenol auto-oxidation accelerates and shortens effective treatment window from 24 to 8 hours.

When the Premix Passes Through a Step-Down Dilution Train Below 0.2% w/w

Premix manufacturing for medicated feed incorporation begins with a 10% w/w Sanwei Quanshen API master premix on a calcium carbonate or rice-hull carrier. The carrier is selected for bulk density matching: the extract powder has a bulk density of 0.35–0.45 g/cm³, and a 40-mesh calcium carbonate carrier of similar density minimizes segregation during pneumatic transfer. Step-down dilution is performed in horizontal ribbon mixers with working capacities of 500–2,000 kg. The first dilution delivers a 2% w/w intermediate premix at a mixing time of 10–15 minutes; the second dilution delivers the final 0.5% w/w premix at 12–18 minutes. Coefficient of variation (CV) for active content is measured per ISO 6497:2002 sampling procedures; a CV below 5% across 10–20 sampling points is the release criterion. The extract’s particle size distribution (D90 typically 80–120 µm after air-jet milling) remains stable through two dilution steps, but electrostatic charge accumulation on low-humidity days (relative humidity below 40%) causes adherence to mixer walls and transfer piping. Grounding of mixer shafts and use of food-grade antistatic agents on flexible hoses reduces wall retention. Final feed inclusion rates for swine and poultry are 0.05–0.2% w/w of the master premix equivalent, corresponding to 0.5–2.0 kg per tonne of finished feed. Batch-to-batch homogeneity is confirmed by near-infrared spectroscopy calibrated against an HPLC reference method for gallic acid and total tannins expressed as gallic acid equivalents. The premix must be protected from moisture ingress: storage at relative humidity above 60% for more than 48 hours causes caking and a loss of flowability measurable as an increase in Hausner ratio from below 1.25 to above 1.45. Desiccant pouches containing 500 g of silica gel per 25-kg bag are standard for tropical distribution routes. Medicated feed containing this premix should not be pelleted above 75 °C because the polyphenol fraction undergoes Maillard-type condensation with amino groups in soybean meal, reducing extractable active markers by 10–15% at 80 °C for 3 minutes. Cold-pellet or mash feed is the recommended carrier form.

Bolus and tablet dosage forms for ruminants require compression characteristics markedly different from those of synthetic small molecules. The extract powder has a Carr index of 28–32% and does not flow acceptably for direct compression without silicified microcrystalline cellulose. A formulation containing 40% w/w API, 45% silicified MCC (SMCC 90), 10% crospovidone, and 5% pregelatinized starch is dry-blended in a V-blender at 25 rpm for 20 minutes. Magnesium stearate is added at only 0.5% w/w because the tannin fraction complexes with divalent magnesium ions, forming hydrophobic films on tablet surfaces that delay disintegration beyond 15 minutes when lubricant concentration exceeds 1.0%. Compression is performed on a rotary tablet press at 10–15 kN main compression force for a 1,200 mg bolus of 19 mm × 9 mm oval tooling. Hardness of 80–120 N is achievable; above 15 kN, capping occurs at the band edge due to elastic recovery of the fibrous extract particles. Friability is tested per USP <1216>; the limit of not more than 1.0% mass loss is met consistently when moisture content of the blend is 2.0–3.5%. Below 2.0% moisture, brittleness rises and friability failures occur; above 3.5%, sticking to punch faces becomes problematic. Disintegration per USP <701> in water at 37 °C is 8–14 minutes for the optimized formulation. Dissolution testing per USP <711> using Apparatus II at 50 rpm in 0.1 M HCl shows 75–85% release of gallic acid marker within 45 minutes. Ruminant boluses are typically administered at 1–2 boluses per 100 kg body weight, but published pharmacokinetic data for this specific extract in rumen fluid is limited. Rumen microflora degrade uncoated polyphenols within 2–4 hours; enteric coating with Eudragit L100-55 is recommended for lower-gastrointestinal delivery, applied at a 6–8% weight gain in a pan coater at 35 °C product temperature.

Lyophilized Parenteral Cake Architecture and Reconstitution Sorption Kinetics

Freeze-dried powders for injectable reconstitution require careful thermal cycle design because the extract contains both glass-forming sugars and crystalline polyphenol phases. Differential scanning calorimetry of the 10% w/v API solution identifies a glass transition temperature of the maximally freeze-concentrated solute at approximately -32 °C to -28 °C, with collapse temperature measured by freeze-dry microscopy at -25 °C ± 2 °C. The lyophilization cycle is therefore designed with primary drying shelf temperature at -35 °C and chamber pressure at 100–150 µbar for 24–36 hours for a 10 mL fill in 20 mL vials. Annealing at -15 °C for 2 hours before primary drying improves cake uniformity by promoting ice crystal growth, which increases effective pore diameter from approximately 5–10 µm to 20–30 µm and shortens primary drying time by 15–20%. Secondary drying shelf temperature is ramped to 25 °C over 6 hours and held for 8–12 hours. Final moisture specification of not more than 2.0% by USP <921> Karl Fischer titration is achievable when the chamber pressure at the end of secondary drying is below 20 µbar. Cake appearance is assessed as a uniform brown to dark-brown porous matrix; collapse at the bottom edge indicates insufficient primary drying temperature margin. Reconstitution time in Water for Injection at 25 °C must be below 60 seconds for field veterinary use. A 10 mL fill reconstituted with 10 mL WFI typically achieves complete dissolution in 25–40 seconds when the cake porosity is within specification. Reconstituted solution must be used within 4 hours because the lyophilized product lacks antimicrobial preservatives. Residual moisture above 2.5% shortens the acceptable shelf life and raises the risk of cake shrinkage during storage at 25 °C/60% RH. Vials are sealed under nitrogen with a residual oxygen level below 1.0% to protect the polyphenol fraction from oxidative condensation. Stability monitoring per VICH GL2 at 25 °C/60% RH and 40 °C/75% RH includes mass balance of gallic acid, total tannins, and non-specific chromophore development at A420. The freeze-dried format is preferred for distribution to tropical regions where liquid injectables would require continuous cold-chain maintenance.The granulation route for oral dosing powders is constrained by the hygroscopic character of the extract and its tendency to sequester water into bound phases. Wet granulation is performed in a top-spray fluid-bed granulator with inlet air temperature at 55–65 °C and product temperature maintained at 35–40 °C. Binder solution is prepared with PVP K30 at 3–5% w/w in purified water, sprayed at a rate of 15–25 g/min/kg of dry powder bed. The endpoint is controlled by loss-on-drying: granules are discharged at 2.0–4.0% moisture. Below 2.0%, the granules become friable and generate excessive fines during subsequent blending; above 4.0%, the granules coalesce into agglomerates exceeding 1,700 µm and cannot meet the sieve specification. Particle size distribution per USP <786> is targeted at not less than 85% retained between 180 µm and 850 µm. The extract’s polyphenol fraction reacts with water during granulation to produce a sticky film on droplet penetration surfaces, which is mitigated by pre-blending the API with 1.0–1.5% colloidal silicon dioxide before spraying binder. The silicon dioxide acts as a moisture scavenger and surface conditioner. After drying and sieving, granules are blended with 0.5% magnesium stearate and 0.5% talc for 5 minutes in a bin blender at 12 rpm. Over-blending beyond 8 minutes causes the magnesium stearate to delaminate from granule surfaces and migrate into the interstices, reducing dissolution rate. The finished granules are filled into foil-lined sachets with desiccant. In-use stability after sachet opening is limited to 7 days when ambient humidity exceeds 65% RH. Oral dosing granules for swine are administered by top-dressing onto feed at 1–2 g per 10 kg body weight. For poultry, granules are dispersed in drinking water by crushing or by formulating a separate water-soluble granule variant using mannitol as the matrix. Published comparative bioavailability data between granule and solution forms of this specific extract are limited.

Hard-Gelatin Capsule Filling Performance Drops When Extract Moisture Exceeds 4.0%

Capsule dosage forms for companion animal use present a flow-critical operation. The extract powder alone is unsuitable for high-speed capsule filling on dosator or tamping-pin machines because its Carr index exceeds the acceptable range for consistent fill weight. A flowable blend is prepared with 30% w/w API, 60% microcrystalline cellulose PH-102, 5% pregelatinized starch, 4% croscarmellose sodium, and 1% colloidal silicon dioxide. The blend is passed through a 30-mesh screen before mixing in a bin blender at 12–15 rpm for 15 minutes. Flow properties after blending are measured: Hausner ratio below 1.25, Carr index below 25%, and mass flow rate through a 10 mm orifice above 8 g/s are the release criteria. Humidity control is the dominant process variable. The extract is hygroscopic; at 60% RH and 25 °C it absorbs 8–12% moisture within 48 hours. When the incoming powder moisture exceeds 4.0%, fill weight variability on a 10,000-capsule-per-hour machine rises from below 2% RSD to 4–6% RSD due to powder bridging in the dosing chamber. The processing suite is maintained at 40–45% RH and 20–22 °C. Capsule shell selection considers the extract’s hygroscopicity: gelatin shells soften and cross-link when they absorb moisture from the fill over time, whereas HPMC shells maintain mechanical integrity but exhibit slower disintegration in water. For gelatin shells, fill moisture must be below 3.0% at encapsulation. For HPMC shells, fill moisture up to 4.0% is tolerable, but dissolution testing per USP <711> in 0.1 M HCl shows a 5–10 minute delay in shell rupture compared with gelatin. Disintegration per USP <701> must not exceed 30 minutes. Capsules are packed in HDPE bottles with induction-sealed caps and 1 g desiccant canisters to maintain headspace relative humidity below 25%. The capsule format is used for companion animal dosing at 50–200 mg extract per kg body weight per day, divided into two administrations. Published multi-dose toxicology data for this specific extract in dogs and cats is limited; the U.S. FDA Center for Veterinary Medicine requires target animal safety data per 21 CFR 514.1(b)(8) before any new animal drug application can proceed.

Powder formulations for topical wound dressing and footbath applications introduce a physicochemical constraint absent from oral and parenteral routes. The tannin fraction of Sanwei Quanshen API binds strongly to collagen in wound exudate and forms a protective protein-tannin coagulum at the tissue interface. This astringent action is the intended pharmacological effect, but it also restricts the release of any co-formulated antibiotic from the same powder matrix. Powders are prepared as a trituration of 20% w/w API with 80% w/w zinc oxide or talc base, passed through a 60-mesh screen, and packaged in 100 g or 500 g low-density polyethylene bottles. Particle size distribution is controlled to D90 below 150 µm for adequate dusting adhesion to moist wound surfaces. The powder is applied at 0.5–1.0 g per wound bed with dressing changes every 12 hours. For bovine footbath use, the powder is dissolved or dispersed at 5–10 g of API per litre of water, but precipitation occurs within 4–6 hours in footbath troughs where zinc sulfate or copper sulfate is also present, because the polyphenol fraction chelates transition metal ions. Separate footbath stations are required: a first station for antibacterial mineral solutions and a second station for the quanshen powder solution, with no mixing between stations. The metal-chelation property is also relevant in premix and feed formulations: elevated iron (above 500 mg/kg of finished feed) reduces extractable polyphenol markers by 8–12% due to iron-polyphenol complexation. Feed mills using ferrous sulfate as a mineral supplement should maintain a time window of at least 4 hours between mineral premix addition and quanshen premix addition unless coated ferrous sulfate or a chelated iron source is used. The powder format for topical use does not require sterile processing, but microbial limits per USP <61> and <62> apply: total aerobic count must not exceed 100 CFU/g, and Staphylococcus aureus and Pseudomonas aeruginosa must be absent in a 1 g sample. Irradiation at 10–15 kGy is used when the API fails bioburden release limits, with no measurable loss of gallic acid marker at doses below 20 kGy.